Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version).
10.3760/cma.j.cn501113-20221215-00602
- VernacularTitle:肝细胞癌免疫联合治疗多学科中国专家共识(2023版)
- Collective Name:Chinese Chapter of the International Hepato-Pancreato-Biliary Association;;Group of Liver Surgery, Surgical Society of Chinese Medical Association;Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology
- Publication Type:Journal Article
- Keywords:
Consensus;
Hepatocellular carcinoma;
Immune checkpoint inhibitors;
Immunocombination therapy;
Immunotherapy;
Multi-disciplinary team
- MeSH:
Humans;
Carcinoma, Hepatocellular/therapy*;
Consensus;
Immunotherapy;
Liver Neoplasms/therapy*
- From:
Chinese Journal of Hepatology
2023;31(1):16-34
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs)-based immunotherapy combined with other treatment for hepatocellular carcinoma (HCC) has achieved significant efficacy in clinical research and practice, and has become the most commonly used and mainstay therapy for the treatment of unresectable HCC. In order to help clinicians administrating immunotherapy drugs and regimens rationally, effectively and safely, we organized a multidisciplinary expert team to adopt the "Delphi" consensus formation method, and finally revised and completed the "Multidisciplinary Expert Consensus on Combination Therapy Based on the Immunotherapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 version. This consensus mainly focuses on the principles and methods of clinical application of combination therapy based on the Immunotherapy, aiming to summarize the recommendations for clinical application based on the latest research and expert experience, and provide application guidance for clinicians.
